Data sourcesSEC Form 45h ago
House PTR5h ago
SEC 13F5h ago
Robinhood Chain5h ago
Public companyAclaris Therapeutics, Inc.
ACRSCIK 0001557746
Price$3.92
1 year+62.7%
Disclosed transactions18
Buys / sells0 / 0
Max Insider Score21
Connections with evidence5
ACRS · disclosed activity on price
| Score | Actor | Security | Side | Value | Executed | Disclosed | Lag | Source | Evidence |
|---|
| 21 | HWHall Jesse WayneChief Medical Officer | ACRSAclaris Therapeutics, Inc. Tax withholding | F | $41K 9,330 sh | May 1, 2026 | May 5, 2026 |
| 9 | HWHall Jesse WayneChief Medical Officer | ACRSAclaris Therapeutics, Inc. Option exercise | M | — 36.4K sh | May 1, 2026 | May 5, 2026 traded May 1, 2026 | +4d | SEC Form 4 | |
| 21 | HWHall Jesse WayneChief Medical Officer | ACRSAclaris Therapeutics, Inc. Option exercise | M | — 36.4K sh | May 1, 2026 | May 5, 2026 traded May 1, 2026 | +4d | SEC Form 4 | |
| 15 | HWHall Jesse WayneChief Medical Officer | ACRSAclaris Therapeutics, Inc. Grant or award | A | — 98.1K sh | Feb 2, 2026 | Feb 6, 2026 traded Feb 2, 2026 | +4d | SEC Form 4 | |
| 15 | BKBalthaser KevinChief Financial Officer | ACRSAclaris Therapeutics, Inc. Grant or award | A | — 99.1K sh | Feb 2, 2026 | Feb 6, 2026 traded Feb 2, 2026 | +4d | SEC Form 4 | |
| 15 | HWHall Jesse WayneChief Medical Officer | ACRSAclaris Therapeutics, Inc. Grant or award | A | — 343.3K sh | Feb 2, 2026 | Feb 6, 2026 traded Feb 2, 2026 | +4d | SEC Form 4 | |
| 15 | BKBalthaser KevinChief Financial Officer | ACRSAclaris Therapeutics, Inc. Grant or award | A | — 346.8K sh | Feb 2, 2026 | Feb 6, 2026 traded Feb 2, 2026 | +4d | SEC Form 4 | |
| 15 | DMDavis Hugh M.Director, President and COO | ACRSAclaris Therapeutics, Inc. Grant or award | A | — 96.1K sh | Feb 2, 2026 | Feb 6, 2026 traded Feb 2, 2026 | +4d | SEC Form 4 | |
| 15 | DMDavis Hugh M.Director, President and COO | ACRSAclaris Therapeutics, Inc. Grant or award | A | — 336.3K sh | Feb 2, 2026 | Feb 6, 2026 traded Feb 2, 2026 | +4d | SEC Form 4 | |
| 15 | KWKolbeck Roland WilhelmChief Scientific Officer | ACRSAclaris Therapeutics, Inc. Grant or award | A | — 95.7K sh | Feb 2, 2026 | Feb 6, 2026 traded Feb 2, 2026 | +4d | SEC Form 4 | |
| 15 | KWKolbeck Roland WilhelmChief Scientific Officer | ACRSAclaris Therapeutics, Inc. Grant or award | A | — 334.9K sh | Feb 2, 2026 | Feb 6, 2026 traded Feb 2, 2026 | +4d | SEC Form 4 | |
| 21 | DMDavis Hugh M.Director, President and COO | ACRSAclaris Therapeutics, Inc. Option exercise | M | — 18.7K sh | Feb 3, 2026 | Feb 5, 2026 traded Feb 3, 2026 | +2d | SEC Form 4 | |
| 21 | BKBalthaser KevinChief Financial Officer | ACRSAclaris Therapeutics, Inc. Option exercise | M | — 22.0K sh | Feb 3, 2026 | Feb 5, 2026 traded Feb 3, 2026 | +2d | SEC Form 4 | |
| 13 | BKBalthaser KevinChief Financial Officer | ACRSAclaris Therapeutics, Inc. Option exercise | M | — 22.0K sh | Feb 3, 2026 | Feb 5, 2026 traded Feb 3, 2026 | +2d | SEC Form 4 | |
| 9 | BKBalthaser KevinChief Financial Officer | ACRSAclaris Therapeutics, Inc. Tax withholding | F | $22K 6,449 sh | Feb 3, 2026 | Feb 5, 2026 traded Feb 3, 2026 | +2d | SEC Form 4 | |
| 21 | DMDavis Hugh M.Director, President and COO | ACRSAclaris Therapeutics, Inc. Option exercise | M | — 18.7K sh | Feb 3, 2026 | Feb 5, 2026 traded Feb 3, 2026 | +2d | SEC Form 4 | |
| 9 | DMDavis Hugh M.Director, President and COO | ACRSAclaris Therapeutics, Inc. Option exercise | M | — 26.8K sh | Dec 2, 2025 | Dec 4, 2025 traded Dec 2, 2025 | +2d | SEC Form 4 | |
| 21 | DMDavis Hugh M.Director, President and COO | ACRSAclaris Therapeutics, Inc. Option exercise | M | — 26.8K sh | Dec 2, 2025 | Dec 4, 2025 traded Dec 2, 2025 | +2d | SEC Form 4 | |
Director, President and COO · Dec 4, 2025